Lineage Cell Therapeutics, Inc. (LCTX) Gross profit 2016–2024
Lineage Cell Therapeutics, Inc. (LCTX) annual gross profit history from SEC filings — each fiscal year as reported.
$9.2MFY2024 · since FY2016: $5.6M → $9.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | $9.2M | +10.8% |
| FY2023 | $8.3M | -40.8% |
| FY2022 | $14.0M | +379.4% |
| FY2021 | $2.9M | +102.3% |
| FY2020 | $1.4M | -53.6% |
| FY2019 | $3.1M | -33.8% |
| FY2018 | $4.7M | +42.4% |
| FY2017 | $3.3M | -40.9% |
| FY2016 | $5.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More LCTX financial trends
LCTX RevenueLCTX Net incomeLCTX Net marginLCTX Gross marginLCTX Operating incomeLCTX Operating marginLCTX Operating cash flowLCTX Free cash flowLCTX Capital expendituresLCTX Return on equityLCTX Stock buybacksLCTX Dividends paidLCTX Total assetsLCTX Total liabilitiesLCTX Shareholders’ equityLCTX overview →